Assessment of relative risk of second primary tumors after ovarian cancer and of the usefulness of double primary cases as a source of material for genetic studies with a cancer registry.
Affiliation
Cancer Research Campaign (CRC) Paediatric and Familial Cancer Research Group, Christie Hospital, Manchester, United Kingdom.Issue Date
1993-08-01
Metadata
Show full item recordAbstract
BACKGROUND: It now is accepted that a small proportion of people with certain forms of cancer have a dominantly inherited gene fault that predisposes them to it. This is more likely with an early age at onset or when the person has had multiple primary tumors. METHODS: Population-based data from the North West Regional Cancer Registry of England regarding 4157 ovarian cancer cases diagnosed between 1980 and 1989 were analyzed to determine the relative risks (RR) of second primary breast and colorectal carcinomas. RESULTS: Elevated risks approaching significance were observed for breast and colorectal carcinoma subsequent to ovarian cancer. After stratification into groups for ovarian histopathologic characteristics and age at onset, significantly elevated risks were obtained for both breast and colorectal tumors after ovarian carcinoma for women younger than 60 years of age at onset and with serous histopathologic characteristics (breast RR, 2.68, P < 0.05; colorectal RR, 4.25, P < 0.05). CONCLUSIONS: These results emphasize the need for greater awareness of the possibility of development of additional cancer after ovarian carcinoma in high-risk groups. Overall, the study supports the theory that breast, colorectal, and ovarian tumors are related genetically.Citation
Assessment of relative risk of second primary tumors after ovarian cancer and of the usefulness of double primary cases as a source of material for genetic studies with a cancer registry. 1993, 72 (3):819-27 CancerJournal
CancerDOI
10.1002/1097-0142(19930801)72:3<819::AID-CNCR2820720330>3.0.CO;2-UPubMed ID
8334636Type
ArticleLanguage
enISSN
0008-543Xae974a485f413a2113503eed53cd6c53
10.1002/1097-0142(19930801)72:3<819::AID-CNCR2820720330>3.0.CO;2-U
Scopus Count
Related articles
- Increased risk of second cancer among patients with ovarian borderline tumors.
- Authors: Bouchardy C, Fernandez S, Merglen A, Usel M, Fioretta G, Rapiti E, Schubert H, Pelte MF, Chappuis PO, Vlastos G
- Issue date: 2008 May
- The genetic epidemiology of second primary breast cancer.
- Authors: Bernstein JL, Thompson WD, Risch N, Holford TR
- Issue date: 1992 Oct 15
- Breast cancer risk factors and second primary malignancies among women with breast cancer.
- Authors: Trentham-Dietz A, Newcomb PA, Nichols HB, Hampton JM
- Issue date: 2007 Oct
- Risk factors for colorectal cancer following breast cancer.
- Authors: Kmet LM, Cook LS, Weiss NS, Schwartz SM, White E
- Issue date: 2003 May
- Incidence of second cancer within 5 years of diagnosis of a breast, prostate or colorectal cancer: a population-based study.
- Authors: Cluze C, Delafosse P, Seigneurin A, Colonna M
- Issue date: 2009 Sep
Related items
Showing items related by title, author, creator and subject.
-
Treatment for non small cell lung cancer, small cell lung cancer and pleural mesothelioma within the EORTC Lung Cancer Group: past, present and future.O'Brien, M; van Meerbeeck, J; Surmont, V; Faivre-Finn, Corinne (2012)
-
Ovarian cancer among 8,005 women from a breast cancer family history clinic: no increased risk of invasive ovarian cancer in families testing negative for BRCA1 and BRCA2.Ingham, S; Warwick, J; Buchan, I; Sahin, S; O'Hara, Catherine; Moran, Anthony; Howell, Anthony; Evans, D; Centre for Health Informatics, Institute of Population Health, The University of Manchester, Manchester, UK. (2013-06)Mutations in BRCA1/2 genes confer ovarian, alongside breast, cancer risk. We examined the risk of developing ovarian cancer in BRCA1/2-positive families and if this risk is extended to BRCA negative families.
-
AZD8186 study 1: phase I study to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and preliminary anti-tumour activity of AZD8186 in patients with advanced castration-resistant prostate cancer (CRPC), squamous non-small cell lung cancer, triple negative breast cancer and with PTEN-deficient/mutated or PIK3CB mutated/amplified malignancies, as monotherapy and in combination with vistusertib (AZD2014) or abiraterone acetate.Lillian, S; De Bono, J; Higano, C; Shapiro, G; Brugger, W; Mitchell, P; Colebrook, S; Klinowska, T; Barry, S; Dean, Emma J; et al. (2016-12)